Abstract
We investigated the effect of WEB 2086, a selective platelet-activating factor (PAF) receptor antagonist, on PAF-induced eosinophil chemotaxis and LTC4 production. WEB 2086 inhibited PAF-induced eosinophil chemotaxis in normals and asthmatics. To further determine if WEB 2086 is a selective PAF receptor antagonist, we examined the effect of WEB 2086 against formyl-methionyl-leucyl-phenylalanine (fMLP)-induced or eosinophil chemotactic factor of anaphylaxis (ECF-A)-induced eosinophil chemotaxis. WEB 2086 did not have a significant inhibition against fMLP or ECF-A-induced eosinophil chemotaxis. These results suggest that WEB 2086 is a selective and potent inhibitor of PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils, due to its antagonism of PAF-receptors.
Similar content being viewed by others
Abbreviations
- PAF:
-
platelet activating factor
- LTC4 :
-
leukotriene C4
- fMLP:
-
formyl-methionyl-leucyl-phenylalanine
- ECF-A:
-
eosinophil chemotactic factor of anaphylaxis
- HBSS:
-
Hank's balanced salt solution
- HPF:
-
high power field
References
F. Snyder,Chemical and biochemical aspects of platelet activating factor: A novel class of acetylated ether-linked choline phospholipids. Med. Res. Rev.5, 107–140 (1985).
C. P. Page, C. B. Archer, W. Paul and J. Morley,Pafacether: A mediator of inflammation and asthma. Trends Pharmacol. Sci.5, 239–241 (1984).
R. N. Pinckard, L. M. McManus, M. Halonen, D. J. Hanahan,Immunopharmacology of acetyl glyceryl ether phosphorlcholine (AGEPC). InImmunopharmacology of the Lung. (Ed. H. H. Newball) Marcel-Dekker, New York, pp. 74–103 (1983).
B. B. Vargaftig, M. Chignard, J. Benveniste, J. Lefort and F. Wal,Background and present status of research on plateletactivating factor. Ann. N.Y. Acad. Sci.370, 119–137 (1981).
H. Darius, D. J. Lefer, J. B. Smith and A. M. Lefer,Role of platelet-activating factor-acether in mediating guinea pig anaphylaxis. Science232, 58–60 (1986).
N. P. Stimler-Gerard,Parasympathetic stimulation is a mechanism for platelet-activating factor-induced contractile reponses in the lung, J. Pharmacol. Exp. Ther.237, 209–213 (1986).
N. Tamura, D. K. Agrawal, F. A. Suliaman and R. G. Townley,Effects of platelet activating factor on the chemotaxis of normodense eosinophils from normal subjects. Biochem. Biophys. Res. Commun.142, 638–644 (1987).
A. J. Wardlaw, R. Moqbel, O. Cromwell and A. B. Kay,Platelet activating factor. A potent chemotactic and chemokinetic factor for human eosinophils, J. Clin. Invest.78, 1701–1706 (1986).
R. N. Pinckard, J. C. Ludwig and L. M. McManus,Plateletactivating factors, InInflammation: Basic principles and clinical correlates. (Eds. J. J. Gallin, I. M. Goldstein, R. Snyderman) Raven Press, New York, pp. 139–167 (1988).
N. Tamura, D. K. Agrawal and R. G. Townley,Leukotriene C 4 production from human eosinophils in vitro. Role of eosinophil chemotactic factors on eosinophil activation. J. Immunol.141, 4291–4297 (1988).
W. S. Adamus, H. Heuer, C. J. Meade and H. M. Brecht,Safety, tolerability, and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects. Clin. Pharmacol. Ther.45, 270–276 (1989).
E. J. Dixon, P. Wilsoncroft, D. N. Robertson and C. P. Page,The effect of PAF antagonists on bronchial hyperresponsiveness induced by PAF, propranolol or indomethacin. Br. J. Pharmacol.97, 717–722 (1989).
M. Soler, M. W. Sielczak and W. M. Abraham,A PAF antagonist blocks antigen-induced airway hyperresponsiveness and inflammation in sheep. J. Appl. Physiol.67, 406–413 (1989).
B. Vargaftig,General pathophysiology of paf. Lung Respir.5, 2–3 (1988).
S. Wallenstein, C. L. Zucker and J. L. Fleiss,Some statistical methods useful in circulation research. Circ. Res.47, 1–9 (1980).
H. M. Brecht,Effects and tolerability of WEB 2086 in healthy volunteers. Lung Respir.5, 8–10 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miyagawa, H., Nabe, M., Hopp, R.J. et al. The effect of WEB 2086 on PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils. Agents and Actions 37, 39–43 (1992). https://doi.org/10.1007/BF01987888
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01987888